resection for gastric metastases . Am J Surg 2001 ; 181 : 279 – 283 . 85. Hermans J Bonenkamp JJ Boon MC . Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials . J Clin Oncol 1993 ; 11 : 1441
Search Results
Modern Surgical Considerations for Gastric Cancer
Quan P. Ly and Aaron R. Sasson
Management of Neuroendocrine Tumors of Unknown Origin
Ariel Polish, Maxwell T. Vergo, and Mark Agulnik
treated similarly to small cell tumors. Locoregional or oligometastatic disease with potential for negative margins for moderately and well-differentiated NETs of unknown primary is generally treated with resection. No efficacious adjuvant therapy is
Is There a Need for Axillary Dissection in Breast Cancer?
Jason P. Wilson, David Mattson, and Stephen B. Edge
2009 ASCO Annual Meeting ; May 30 – June 2 , 2009 ; Orlando, Florida . Abstract CRA506 . 28. Straver ME Meljnen P van Tienhoven G . Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant
Trastuzumab-Related Cardiac Dysfunction
Melinda L. Telli and Ronald M. Witteles
a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 . J Clin Oncol
Developing a Referral System for Fertility Preservation Among Patients With Newly Diagnosed Cancer
Gwendolyn P. Quinn, Susan T. Vadaparampil, Clement K. Gwede, Joyce D. Reinecke, Tina M. Mason, and Celso Silva
Knobf MT . The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors . Oncologist 2006 ; 11 : 96 - 110 . 10 Schover LR . Motivation for parenthood after cancer: a review . J
First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition
Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang
50% of these tumors overall. 19 Responses to targeted therapies have generally been better with fewer prior lines of treatment, and recent trials have shown that BRAF -directed therapy may be used upfront as adjuvant therapy in resected stage III
Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer
Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk
after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomized, double-blind, placebo-controlled, phase 3 trial . Lancet Oncol 2017 ; 18 : 1688 – 1700 . 28. Gradishar WJ Anderson BO Abraham J . NCCN
Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer
Kathryn P. Pennington, Renata R. Urban, and Heidi J. Gray
13% of those in the open group had positive lymph nodes, and parametrial involvement was present in 7% and 4% of individuals in each group, respectively. Similar rates of postoperative adjuvant therapy were administered in both groups (29% in MIS
Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers
Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell
factor, and is considered an indication for intensive adjuvant therapy. Radiographic predictive power for extranodal extension has uncertain reliability. Unambiguous clinical evidence of extranodal invasion includes invasion of the skin, fixation to
An Infant-Type Hemispheric Glioma With SOX5::ALK: A Novel Fusion
Chia Chin Tsai, Man-Hsu Huang, Chia-Lang Fang, Kevin Li-Chun Hsieh, Tsung-Han Hsieh, Wan-Ling Ho, Hsi Chang, Min-Lan Tsai, Yu-Chien Kao, James S. Miser, Tai-Tong Wong, Min-Yu Su, and Yen-Lin Liu
were found in 5 patients with evaluable disease, with durable response or event-free survival lasting for 6 to 22 months in 6 of 7 patients. This suggests that lorlatinib may serve as both neoadjuvant and adjuvant therapy in future clinical trials of
